WARNING: FETAL TOXICITY
When pregnancy is detected, discontinue TARKA as soon as possible.
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (see WARNINGS: Fetal Toxicity).
TARKA├é┬« (trandolapril/verapamil hydrochloride ER) combines a slow release formulation of a calcium channel blocker, verapamil hydrochloride, and an immediate release formulation of an angiotensin converting enzyme inhibitor, trandolapril.
TARKA is indicated for the treatment of hypertension.
This fixed combination drug is not indicated for the initial therapy of hypertension (DOSAGE and ADMINISTRATION).
In using TARKA, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that trandolapril does not have similar risk (see WARNINGS: Neutropenia/Agranulocytosis).
Media Articles Related to Tarka (Trandolapril / Verapamil)
Hard-to-treat hypertension may jeopardize sleep apnea patients' heart health
Source: Cardiovascular / Cardiology News From Medical News Today [2016.07.19]
In a study of patients with hypertension, those with resistant hypertension - meaning that their blood pressure remained elevated despite concurrent use of three antihypertensive agents of...
Stroke is largely preventable, with hypertension confirmed as biggest risk factor, according to global study
Source: Hypertension News From Medical News Today [2016.07.18]
Ten potentially modifiable risk factors account for 90% of strokes worldwide, but regional variation should be considered, says study.
Prehypertension during pregnancy could lead to cardiovascular risks
Source: Hypertension News From Medical News Today [2016.06.28]
Pregnant women who experience persistent blood pressure elevations in the upper ranges of normal may be at high risk of developing metabolic syndrome and increased cardiovascular risk after giving...
Blood test shows promise in gauging severity of pulmonary arterial hypertension
Source: Respiratory / Asthma News From Medical News Today [2016.06.22]
Johns Hopkins Medicine researchers report that rising blood levels of a protein called hematoma derived growth factor (HDGF) are linked to the increasing severity of pulmonary arterial...
The healing powers of music: Mozart and Strauss for treating hypertension
Source: Hypertension News From Medical News Today [2016.06.21]
The music of Mozart and Strauss is able to lower blood lipid concentrations and the heart rate.
Published Studies Related to Tarka (Trandolapril / Verapamil)
Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST). [2005.07]
BACKGROUND: The INternational VErapamil SR-Trandolapril Study (INVEST), a prospective, randomized, antihypertensive trial, found that two different medication regimens produced similar blood pressure (BP) control with equivalent cardiovascular (CV) outcomes (death from any cause, nonfatal myocardial infarction [MI], or nonfatal stroke). HYPOTHESIS: The study was undertaken to investigate whether differences exist by global regions in demographics, treatment, and outcomes in the INVEST trial... CONCLUSIONS: In INVEST, regional differences in medication utilization, BP control, and CV outcomes were identified. These disparities warrant further investigation to define appropriate care for patients with hypertension and stable CAD from an international public health perspective.
The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. [2004.07]
CONCLUSIONS: Our results suggest that FDTV is more effective than trandolapril in reducing proteinuria in normotensive, type 2 diabetic patients. This effect on proteinuria is not related with blood pressure reduction.
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. [2003.12.03]
CONTEXT: Despite evidence of efficacy of antihypertensive agents in treating hypertensive patients, safety and efficacy of antihypertensive agents for coronary artery disease (CAD) have been discerned only from subgroup analyses in large trials. OBJECTIVE: To compare mortality and morbidity outcomes in patients with hypertension and CAD treated with a calcium antagonist strategy (CAS) or a non-calcium antagonist strategy (NCAS)... CONCLUSION: The verapamil-trandolapril-based strategy was as clinically effective as the atenolol-hydrochlorothiazide-based strategy in hypertensive CAD patients.
The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study. [2003.07]
BACKGROUND: We tested whether the combination of verapamil (V) or amlodipine (A) with trandolapril (T) affected proteinuria differently from T alone in patients with nondiabetic nephropathies... CONCLUSION: In patients with nondiabetic proteinuric nephropathies treated with T, the combination of V or A does not significantly increase its antiproteinuric effect.
Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. [2003.05]
BACKGROUND: There is evidence that diuretics and beta blockers impair glucose tolerance, whereas calcium channel blockers and angiotensin converting enzyme blockers lack this metabolic effect. We compared the effect of a combination therapy with a nondihydropyridine calcium channel blocker plus an angiotensin converting enzyme inhibitor and a beta blocker plus a diuretic on hemoglobin A(1c) (Hb A(1c)) in patients with type 2 diabetes and mild-to- moderate hypertension... CONCLUSIONS: HbA(1c) and other parameters of short- and long-term glycemic control were in a more favorable range after antihypertensive treatment with verapamil SR plus trandolapril as compared with atenolol plus chlorthalidone.
Clinical Trials Related to Tarka (Trandolapril / Verapamil)
Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR) [Completed]
The primary objective of this study is to determine whether impaired glucose tolerance is
improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome
Tarka« vs. Lotrel« in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM) [Completed]
The primary objective of this study is to determine if trandolapril/verapamil (Tarka«) is
superior to amlodipine/benazepril (Lotrel«) in reduction of albuminuria in hypertensive
subjects with Type 2 diabetes mellitus (DM) and diabetic nephropathy
Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension [Completed]
This study will investigate antihypertensive activity and safety profile of Tarka in Russian
hypertension patients by ambulatory blood pressure measurement (ABPM)
Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka« Fixed Combination in Patients With Essential Hypertension [Completed]
The fixed combination of verapamil SR/trandolapril (Tarka«) is an effective, well-tolerated
therapy for the treatment of essential hypertension in those who require more than one agent
to achieve optimal blood pressure (BP) control. The endpoint is compliance with Tarka«
treatment by number/percentage of patients continued on fixed combination Tarka therapy
after six months. This Post Marketing Observational Study will be conducted in a
prospective, single-arm, single-country, multicenter format. The investigational sites will
be the cardiologists, the doctors of internal medicine and general practicians. Since this
will be a Post Marketing Observational Study, Tarka┬« will be prescribed in usual manner in
accordance with the terms of the local market authorization with regards to dose, population
and indication as well as the local guidelines.
Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL) [Completed]
The TRAIL study was conducted to examine the effects of escalating doses of an ACE
inhibitor, trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.
Reports of Suspected Tarka (Trandolapril / Verapamil) Side Effects
Renal Failure Acute (11),
Renal Tubular Disorder (5),
Drug Interaction (5),
Agitation (4), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Tarka has an overall score of 9. The effectiveness score is 10 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
Tarka review by 51 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || hypertension|
|Dosage & duration:|| || 240/40 (dosage frequency: once daily) for the period of been taking for couple of years|
|Other conditions:|| || hypothyroidism|
|Other drugs taken:|| || synthyroid|
|Benefits:|| || very effectively reduced my blood pressure to a good level and has amitianed it for the 2+ years I have been taking it.|
|Side effects:|| || My lungs feel heavy at times and that produces a hacking cough. It's not all the time, just occasionally. It hasn't been bothersome enough to ask about changing it to something else yet.|
|Comments:|| || I'm taking one pill that contains two different blood pressure medications.
It has been very effective in controlling my hypertension.|
Page last updated: 2016-07-19